BioCryst Pharmaceuticals, Inc. (BCRX)

4.1750 -0.0950 (-2.23%) As of 10:33AM EDT. Market open.

BioCryst Pharmaceuticals, Inc.

4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919 859 1302
https://www.biocryst.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 536

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jon P. Stonehouse	CEO, President & Executive Director	1.23M	647.14k	1961
Mr. Anthony J. Doyle	Senior VP, CFO & Treasurer	845.93k	N/A	1980
Ms. Alane P. Barnes	Senior VP, Chief Legal Officer & Corporate Secretary	794.75k	N/A	1966
Ms. Jinky Ang Rosselli	Chief Data & Insights Officer	N/A	N/A	N/A
Mr. Philip George	Chief Strategy Officer	N/A	N/A	N/A
Mr. Clayton Fletcher	Chief Business Development Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Corporate governance

BioCryst Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.